Summary
Johnson & Johnson (JNJ) announced a change in the reporting format for its Medical Devices segment, effective with the fourth quarter of 2015. This change aims to provide investors with greater clarity and detail regarding the performance of its Orthopaedics and Surgery businesses. The new structure breaks down the Medical Devices segment into more granular categories, offering a clearer view of sub-segment growth drivers.
Key Highlights
- 1JNJ is enhancing its sales reporting for the Medical Devices segment to provide better clarity.
- 2The new format will offer more detailed reporting for the Orthopaedics and Surgery businesses.
- 3Specific sub-categories within Orthopaedics now include Hips, Knees, Trauma, and Spine & Other.
- 4The Surgery business is now segmented into Advanced, General, and Specialty categories for reporting.
- 5Reporting for Cardiovascular (renamed from Cardiovascular Care), Diabetes Care, Diagnostics, and Vision Care remains unchanged.
- 6The Pharmaceutical and Consumer segments' sales reporting are unaffected by this change.
- 7Historical sales data (Q1-Q3 2015, full year 2014, and Q1-Q4 2014) in the new format is provided to aid comparison.
Frequently Asked Questions
Johnson & Johnson is implementing this change to provide investors with greater clarity and a more detailed understanding of the sales performance within its Orthopaedics and Surgery businesses.
The Orthopaedics business will now be reported with a more granular breakdown, including specific categories for Hips, Knees, Trauma, and Spine & Other.
The Surgery business will be reported across three new categories: Advanced (including Endocutter and Adhesion Prevention, Energy and Biosurgery), General (including Wound Closure, Mechanical, Women’s Health, Hernia Repair), and Specialty (including Acclarent, Infection Prevention, Mentor, Steri-Med, and Sedasys).
No, this change specifically affects the Medical Devices segment. Sales reporting for the Pharmaceutical and Consumer segments will remain the same.